Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an update.
Prescient Therapeutics Limited announced a change in the director’s interest, with James Campbell acquiring 5,257,573 unlisted options exercisable at $0.10, expiring on 17 November 2029. This change was approved by shareholders at the company’s Annual General Meeting, indicating strategic alignment and potential growth opportunities for the company.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in advancing targeted and personalized medicine approaches to improve treatment outcomes for cancer patients.
Average Trading Volume: 934,319
Technical Sentiment Signal: Hold
Current Market Cap: A$60.99M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.